Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03075670 · ClinicalTrials.gov registry record · Phase 1
A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03075670 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 15 participants.
The verdict
NCT03075670, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This trial is conducted in Europe and the United States of America. The aim of this trial is to compare the pharmacokinetics (the exposure of the trial drug in the body) of nonacog beta pegol (N9-GP) and ALPROLIX® in patients with haemophilia B.
Interventions
- DRUG N9-GP
- DRUG ALPROLIX®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-03-07 |
| Est. Completion | 2017-12-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03075670
The ClinicalTrials.gov registry entry for NCT03075670 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which N9-GP is the first listed.
NCT03075670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03075670 about?
NCT03075670 is a clinical study titled "A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B". This trial is conducted in Europe and the United States of America. The aim of this trial is to compare the pharmacokinetics (the exposure of the trial drug in the body) of nonacog beta pegol (N9-GP) and ALPROLIX® in patients with haemophilia B.
What is the current status of trial NCT03075670?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2017-03-07. Estimated completion is 2017-12-08.
What interventions are being tested in trial NCT03075670?
The interventions under investigation include: N9-GP (DRUG), ALPROLIX® (DRUG).
Who is sponsoring clinical trial NCT03075670?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.